Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9078MR)

This product GTTS-WQ9078MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ9078MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2231MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aVWF81
GTTS-WQ11936MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MLN2045
GTTS-WQ13069MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ8022MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GZ-402668
GTTS-WQ8545MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ14441MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ4233MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ9874MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA K7153A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW